| Document |
Document Title |
|
WO/1983/000335A1 |
New derivative of vitamin D, 26,26,26,27,27,27-hexafluoro-1alpha,25-dihydroxycholecalcife
rol, a process for preparing the same, and novel intermediate compounds. The compound is characterized by vitamin D-like activity substantially gre...
|
|
WO/1982/004051A1 |
A mixture of a 25-hydroxylated vitamin D derivative and a 1(Alpha)-hydroxylated vitamin D derivative suitable for use in preventing parturient paresis in dairy cattle.
|
|
WO/1982/003175A1 |
Waster-soluble complex compounds obtained by binding albumin to a half ester of organic dibasic acid such as succinic acid or phthalic acid with 7-hydroxycholesterol, represented by the general formula: (FORMULA) wherein R represents a p...
|
|
WO/1982/002893A1 |
New derivatives of vitamin D3, specifically, 1(Alpha), 25-dihydroxy-2(Beta)-fluorocholecalciferol. The compound is characterized by vitamin D-like activity as measured by its ability to stimulate intestinal calcium transport, mobilizatio...
|
|
WO/1982/000465A1 |
Methods for preparing the various isomeric forms of 25-hydroxyvitamin D3-26, 23-lactone utilizing cyanohydrin formation with readily prepared steroid materials followed by actinic radiation of the products and recovery of the desired 25-...
|
|
WO/1981/003023A1 |
New derivatives of vitamin D3, specifically, 1(Alpha)-hydroxy-2(Alpha)-fluorocholecalciferol. The compound is characterized by vitamin D-like activity as measured by its ability to stimulate intestinal calcium transport, mobilize calcium...
|
|
WO/1981/002427A1 |
Process for the fermentation of bile which includes the step of cultivating one or more aerobic microorganisms which have the ability to selectively degrade bile acids or bile acid conjugates contained in bile. The fermentation is carrie...
|
|
WO/1981/002298A1 |
New derivative of vitamin D, 25-hydroxy-26,26,26,27,27,27-hexafluoro cholecalciferol and process for preparing the same. The compound is characterized by vitamin D-like activity in their ability to increase intestinal calcium transport, ...
|
|
WO/1980/002502A1 |
New vitamin D derivatives as well as new intermediate compounds derived during the processes for preparing such new derivatives. The new derivatives have been identified as 1(Alpha)-hydroxy-25-keto-27-nor-vitamin D3 and its acylates. 1(A...
|
|
WO/1980/002562A1 |
Isotopically labeled vitamin D compounds, including radiolabeled vitamin D compounds of high specific activity, methods for their preparation, and novel intermediates in their synthesis. The radiolabeled vitamin D compounds are character...
|
|
WO/1980/002098A1 |
Isoflavones and related compounds useful as antioxidants and in antioxidant compositions including edible fats and oils. Many of these compounds can be recovered from tempeh, a fermented soybean product, Others can be prepared by chemica...
|
|
WO/1980/002027A1 |
Ergostadientriols which may be recovered from either the fungus R. oligosporus or the fungus R. oryzae as well as from soybeans which have been fermented with either of these fungi. Alternatively, the sterols may be chemically synthesize...
|
|
WO/1980/001915A1 |
New derivative of vitamin D3,24,24-difluoro-25-hydroxycholecalciferol. The compound is characterized by vitamin D-like activity in its ability to increase intestinal calcium transport, increase serum calcium and inorganic phosphorous con...
|
|
WO/1979/000513A1 |
The principal object of the invention is to provide a method for directly introducing an oxygen function at carbon 1 of the vitamin D molecule or precursors or derivatives thereof which comprises subjecting such molecule to allylic oxida...
|
|
JP2024093001A |
To manufacture a resist pattern with good pattern collapse resistance (PCM). The present invention relates to a carboxylic acid generator that contains a carboxylate represented by formula (I). [Selection diagram] None
|
|
JP7510648B2 |
Provided herein are halogenated cholesterol analogues, including methods of making and using the same. Also provided are methods of making radiolabeled cholesterol analogues including admixing an epoxide with a fluorine-18 source under c...
|
|
JP7510461B2 |
Described herein are neuroactive steroids of the Formula (I):or a pharmaceutically acceptable salt thereof; wherein - - - - - -, R1, R2a, R2b, R3and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behav...
|
|
JP2024088648A |
The present invention provides a compound that is useful for treating or preventing diseases and symptoms such as non-alcoholic steatohepatitis and primary biliary cholangitis. The present invention provides a compound of formula (I) or ...
|
|
JP7503063B2 |
Compounds of general formula (1):wherein R1, R2 and R3 are as defined herein;are of use in the treatment and prevention of neurodegenerative disorders including Alzheimer's disease and Parkinson's disease.
|
|
JP7502186B2 |
The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.
|
|
JP2024080672A |
A resist pattern is produced with good line edge roughness (LER). The present invention relates to an acid generator comprising a salt represented by formula (I). [Selection diagram] None
|
|
JP7498804B2 |
The present invention relates to: a deoxycholic acid-peptide conjugate having anti-obesity activity by inhibiting lipid production and promoting lipolysis; and a use for preventing, ameliorating or treating obesity comprising the conjuga...
|
|
JP2024077330A |
The present invention provides a resist composition that has high sensitivity and excellent lithography properties, a method of forming a resist pattern using the resist composition, a polymer compound that can be used in producing the r...
|
|
JP2024522018A |
The present invention relates to the synthesis of cholesterol, which is obtained through a ring-opening step of a compound of formula (I), followed by activation and reduction steps. The present invention also relates to intermediates ob...
|
|
JP2024069502A |
The present invention provides substituted oxysterols that are useful for preventing and/or treating a wide range of disorders. [Solution] Formula (A): and pharma- ceutically acceptable salts and pharmaceutical compositions thereof, wher...
|
|
JP2024040444A |
To provide methods of treating diseases.Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, where n, R19, R5, R3a, R6a, R6b, R1, R2a, R2b, R4a, R4b, R7a, R7b, R11a, R11b, R12a, R12b, R17b, R15a, R1...
|
|
JP2024510146A |
The invention particularly relates to methods of producing sulfated oligosaccharide derivatives and intermediates thereof. The sulfated oligosaccharide derivatives have the following formula (I), where X and Y are any D- or L-hexose or p...
|
|
JP2024509902A |
The present invention includes a novel amino acid derivative, a method for producing the same, and a method for producing the same.Bhepatitis orDIt relates to a pharmaceutical composition for the treatment of hepatitis type, comprising t...
|
|
JP2024028631A |
To provide oxysterols and methods of use thereof.The present invention provides compounds according to a Formula (I) in the figure and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. In the formula, R2...
|
|
JP2024020310A |
The present invention provides a method for producing mogrol glycosides and other triterpenoid compounds using recombinant microbial host cells. The present invention provides mogrol, including minor products of Siraitia grosvenorii, mog...
|
|
JP2024019459A |
[Problem] To provide a new compound Disclosed herein are novel compounds, pharmaceutical compositions containing such compounds, and related methods of use thereof. The compounds described herein are useful, for example, as liposomal del...
|
|
JP2024505449A |
This disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials, and methods of using them.
|
|
JP2024001871A |
An object of the present invention is to provide a salt, an acid generator, a resist composition, etc. that can produce a resist pattern with good CD uniformity. A salt represented by formula (I), an acid generator, and a resist composit...
|
|
JP2024001870A |
An object of the present invention is to provide a carboxylic acid salt, a resist composition, etc., which can produce a resist pattern having good resistance to pattern collapse. A carboxylic acid salt represented by formula (I), a carb...
|
|
JP7410062B2 |
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, and R8 are as defined herein. Compounds of the present invention are cont...
|
|
JP7382946B2 |
The present invention provides host cells and methods for making mogrol glycosides, including Mogroside V (Mog. V), Mogroside VI (Mog. VI), Iso-Mogroside V (Isomog. V), and glycosylation products that are minor products in Siraitia grosv...
|
|
JP7375685B2 |
A chemically amplified resist composition comprising a quencher containing an ammonium salt of a carboxylic acid having an iodized or brominated hydrocarbyl group exclusive of an iodized or brominated aromatic ring and an acid generator ...
|
|
JP7365082B2 |
The present invention discloses a synthesis method of ursodeoxycholic acid by using the plant-derived compound BA as a raw material to synthesize ursodeoxycholic acid through the steps of ethylene glycol or neopentyl glycol protection, o...
|
|
JP7361715B2 |
Provided is a method for producing high-purity cholesterol which does not contain a substantial amount of desmosterol, said method comprising reacting cholesterol mixed with desmosterol with a halogenating reagent and water and then sepa...
|
|
JP7344983B2 |
The present invention relates to a method for preparing a chenodeoxycholic acid derivative. Particularly, disclosed is a method for carrying out one-pot reduction on a compound represented by Formula (VI), i.e., 3α-hydroxyl-ethidene-7-k...
|
|
JP2023126904A |
To provide new oxysterols that modulate an NMDA receptor for the prevention and treatment of conditions associated with the NMDA expression and function.The invention provides compounds according to Formula (I) in the figure, and pharmac...
|
|
JP2023538133A |
Prodrugs that target the low-density lipoprotein receptor (LDLR) and contain acid- and/or enzymatically-cleavable acetal- or oxybenzyloxy-linked carbonate or carbamate linkages are described. Also described are core-shell nanoparticles c...
|
|
JP2023536515A |
Regarding prodrugs of ester derivatives of inotodiol and their uses, said prodrugs not only have increased solubility in inorganic and organic solvents, but also have improved stability to treat various inflammations, including inflammat...
|
|
JP2023111289A |
To provide new lithocholic acid derivatives with sufficient vitamin D3 activity.The invention provides a compound represented by the general formula (I) in the figure, a salt thereof, or a prodrug thereof. (In the formula, R1 and R2 each...
|
|
JP7317898B2 |
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3a, R3b, R4, R5a, R5b, R6a, and R6b are as defined herein. Compounds of the present ...
|
|
JP2023104925A |
To provide novel solid forms (e.g., crystalline forms) of berberine ursodeoxycholate (BBR-UDCA) having one or more desirable properties, such as high stability, high crystallinity, high purity, low hygroscopicity, favorable dissolution p...
|
|
JP7311921B2 |
The present invention relates to the field of pharmaceutical chemistry, and specifically to a method for preparing cholesterol, a derivative thereof, and an analog thereof. The derivative of cholesterol comprises, but is not limited to, ...
|
|
JP7308886B2 |
Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated use...
|
|
JP7308811B2 |
The present invention falls within the field of pharmaceutical chemistry, and relates to a method for preparing a steroid derivative FXR agonist and relevant intermediates. In particular, the present invention relates to a method for pre...
|
|
JP7304444B2 |
Compounds are provided according to Formula (A):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R5, R6, and RG are as defined herein. Compounds of the present invention are ...
|
